BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie presented Phase 2 ADDRESS-LC data on bezisterim (NE3107) in Long COVID at the American Neurological Association annual meeting, with results from 203 patients published in Annals of Neurology. The trial showed only a trend toward improvement in the overall intent-to-treat population, but patients with severe baseline fatigue, PEM, or cognitive impairment — about 78% of participants — had statistically significant improvements. Among the most fatigued half, PROMIS Fatigue improved 8.93 points on bezisterim vs 5.30 on placebo (p=0.02). Safety was comparable to placebo, with fewer treatment-emergent adverse events on drug (41.6% vs 55.9%) and no serious events in the bezisterim group.
Key figures
- Drug Name
- bezisterim (NE3107)
- Phase Of Trial
- Phase 2
- Nct number
- NCT06847191
- Trial name
- ADDRESS-LC
- Dow funding
- $13.13 million
- Patients enrolled
- 203
- Te ae placebo pct
- 55.9%
- Te ae bezisterim pct
- 41.6%
- Promis fatigue p value
- 0.02
- Treatment duration weeks
- 12
- Promis fatigue improvement placebo
- 5.3
- Promis fatigue improvement bezisterim
- 8.93
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.